Biogen Inc.

07/13/2026 | Press release | Distributed by Public on 07/13/2026 15:40

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Biogen Inc. published this content on July 13, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 13, 2026 at 21:40 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]